CMS Hungary has advised Egis Pharmaceuticals Plc. on the acquisition of one of Hungary’s well-known, locally applied dermatological product lines from Teva Pharmaceutical Industries Ltd.
The acquisition holds strategic significance for Egis, a Hungary-based pharmaceutical company with a 110-year history. This move aims to solidify its position in the Hungarian over-the-counter (OTC) market while expanding its portfolio of locally applied dermatological products.
The CMS team was led by Eszter Török (Corporate) and included Dóra Petrányi (TMIC); Szabolcs Szendrő and Aranka Nagy (both Competition); Veronika Kovács (Lifesciences); and Miklós Boros (Commercial).
